Side by Side
Authorization status is the row people most often get wrong — two of these three are fully approved and one is not approved at all.
| Paxlovid nirmatrelvir + ritonavir | Veklury remdesivir, outpatient | Lagevrio molnupiravir | |
|---|---|---|---|
| Status | FDA approved for high-risk adults; ages 12–17 (≥40 kg) may be covered under an emergency use authorization, though guidance here is fluid | FDA approved, adults and pediatric patients including neonates ≥1.5 kg | Not approved. May be available under an emergency use authorization, only when other authorized treatments are inaccessible or clinically inappropriate, though guidance here is fluid |
| How it is taken | Oral tablets, at home, twice daily for 5 days | Intravenous infusion — 3 daily infusions at a clinic or infusion centre | Oral capsules, at home, twice daily for 5 days |
| Start window | Within 5 days of symptom onset | Within 7 days of symptom onset | Within 5 days of symptom onset |
| Mechanism | Nirmatrelvir blocks the main protease (Mpro); ritonavir is a booster that slows its breakdown | Nucleotide prodrug; inhibits the RNA-dependent RNA polymerase | Ribonucleoside analogue; introduces errors into viral RNA ("error catastrophe") |
| Pivotal trial result | 89.1% relative risk reduction in COVID-related hospitalization or death when started within 3 days — 0.77% (3/389) vs 7.01% (27/385), and 0 deaths vs 7 (EPIC-HR) | 87% reduction in hospitalization or death vs placebo (PINETREE) | ≈30% reduction — 7.3% (28/385) vs placebo at the interim analysis (MOVe-OUT) |
| Who the trial studied | All three pivotal trials enrolled unvaccinated adults, in 2021. None of these headline numbers describes a vaccinated population in 2026. See below. | ||
| Main constraint | Drug interactions — ritonavir inhibits CYP3A; see the next section | Logistics — three trips for IV infusion; no ritonavir interaction problem | Efficacy and status — weakest result, not approved (emergency authorization at most; status fluid), not recommended in pregnancy |
| Typically used when | First-line for eligible high-risk outpatients with a compatible medication list | Paxlovid interactions are prohibitive, or the 5-day window has passed but 7 days have not | Neither of the other two is available or appropriate |
The Interaction Problem — Why Paxlovid Gets Refused
This is the part of the comparison that most affects real prescriptions, and the part most comparison articles leave at "check with your doctor."
Paxlovid is two drugs. Nirmatrelvir does the antiviral work; ritonavir does none of it. Ritonavir is there purely as a pharmacokinetic booster — it inhibits the CYP3A enzyme system so the body clears nirmatrelvir more slowly and blood levels stay high enough to work. That is also the source of the entire interaction problem, because CYP3A metabolises a very large share of commonly prescribed medicines.
The consequences run in two directions, and conflating them is the usual source of confusion:
- Paxlovid raises levels of other drugs. For medicines cleared by CYP3A, blocking that clearance can push concentrations into the toxic range. Where the toxicity is serious and dose-related — certain statins, some antiarrhythmics, some sedatives — the FDA label lists the combination as contraindicated. For others, including some anticoagulants and transplant immunosuppressants such as tacrolimus and cyclosporine, the answer is dose adjustment or specialist supervision rather than outright avoidance.
- Other drugs lower Paxlovid's levels. Strong CYP3A inducers — rifampin, carbamazepine, phenytoin, St John's wort — speed clearance and can drop nirmatrelvir below the concentration that works. Because induction persists after the inducer is stopped, this is not fixed by pausing the other drug for five days.
What this means practically. "Can I take Paxlovid?" is answered by a pharmacist or prescriber reading your full current medication list against the label — including over-the-counter products and supplements, which is where St John's wort and some herbal preparations catch people out. Some interactions are managed by holding a medicine for the five-day course; some are not. Do not stop, pause or adjust any prescribed medicine on the strength of a web page, including this one. Bring the list; ask the question.
Two things follow from this that are genuinely useful to know in advance. First, the reason remdesivir is the standard alternative is not that it is better — it is that it does not carry the ritonavir problem at all. Second, "you can't have Paxlovid" is usually a statement about your medication list or your timing, not a judgement that you are not at risk. It is worth asking which one it was, because the answer determines whether an alternative exists.
Read the Headline Numbers Correctly
Every one of those percentages comes from an unvaccinated population
EPIC-HR enrolled "symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe Covid-19." MOVe-OUT enrolled "nonhospitalized, unvaccinated adults with mild-to-moderate, laboratory-confirmed Covid-19 and at least one risk factor." PINETREE ran in the same period and population. These were 2021 trials, conducted before widespread vaccination and before the current variant landscape.
That does not make the drugs ineffective now — it means the headline numbers are an upper bound measured against a placebo group with no prior immunity. Real-world effectiveness in a vaccinated population is consistently lower, while remaining most meaningful for the groups with the highest baseline risk: older adults and the immunocompromised. Any comparison that quotes "89% effective" in 2026 without that sentence is quoting a number out of its population.
89% versus 87% is not a ranking
Paxlovid and remdesivir were never compared head to head. Their numbers come from separate trials with different protocols, different endpoints in detail, and different treatment windows, so the one-point gap between them carries no information. What separates them in practice is everything in the "main constraint" row: oral at home versus three infusion appointments, and a ritonavir interaction list versus none.
Molnupiravir's ≈30% is a different matter — that gap is large enough to be meaningful, and it is why its authorization is conditional on the alternatives being unavailable or inappropriate rather than being a free choice.
Rebound, and what is actually known
Symptoms or a positive test returning two to eight days after finishing Paxlovid is real and commonly cited at around 5–10%, though estimates vary widely with how rebound is defined and measured. Two things are worth holding onto: rebound is generally mild and self-limiting, and there is no evidence that a second course improves outcomes — it is not a labelled use. Rebound has also been observed in people who received no antiviral, which is why attributing it to the drug specifically remains contested rather than settled.
Frequently Asked Questions
Which COVID antiviral is most effective?
On trial numbers, Paxlovid (89.1% relative risk reduction, EPIC-HR) and remdesivir (87%, PINETREE) are far ahead of molnupiravir (≈30%, MOVe-OUT) — but all three trials studied unvaccinated adults in 2021, and none compared the drugs against each other. Effectiveness in vaccinated people is lower across the board, while still mattering most for older and immunocompromised patients.
Why was I refused Paxlovid?
Usually drug interactions or timing rather than a judgement about your risk. Ritonavir inhibits CYP3A, making Paxlovid contraindicated with some medicines and dose-adjusted with others, and strong CYP3A inducers can render it ineffective. The other common reason is the five-day window from symptom onset. Ask which it was — it determines whether remdesivir is an option.
Can I take remdesivir at home?
No — the outpatient course is three intravenous infusions at a clinic or infusion centre, started within seven days of symptom onset. That burden is why it is used less than Paxlovid despite comparable trial results, and why it is the usual fallback when Paxlovid's interactions rule it out.
Is molnupiravir FDA approved?
No. It has never been FDA approved. It may be available under an emergency use authorization, conditional on other authorized treatments being inaccessible or clinically inappropriate, though guidance here is fluid — check FDA's current list. It is also not recommended in pregnancy, because of a theoretical mutagenic risk arising from its error-catastrophe mechanism. Paxlovid is fully approved for adults (ages 12–17 may be covered under an emergency use authorization, though guidance here is fluid); remdesivir is fully approved including for pediatric patients.
What about the drugs that failed?
Hydroxychloroquine and ivermectin were both tested in large randomised trials and neither showed benefit for COVID-19. They are covered, with the trial evidence, on our misinformation page.
Medical disclaimer. This page compares published labelling and trial evidence. It is informational and is not medical advice, not a recommendation for or against any treatment, and not a substitute for a prescriber who can see your history and your full medication list. Antiviral eligibility depends on individual risk factors, current medicines, timing and local availability. Authorization status and labelling change — verify against the FDA label before acting on anything here.
Sources & References
- Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19 (EPIC-HR). N Engl J Med 2022;386(15):1397–1408. doi:10.1056/NEJMoa2118542
- Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients (PINETREE). N Engl J Med 2022;386(4):305–315. doi:10.1056/NEJMoa2116846
- Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients (MOVe-OUT). N Engl J Med 2022;386(6):509–520. doi:10.1056/NEJMoa2116044
- Pfizer / U.S. Food and Drug Administration. PAXLOVID (nirmatrelvir and ritonavir) prescribing information (label revised February 2026) — indication, contraindications and drug-interaction sections. DailyMed
- U.S. Food and Drug Administration. Veklury (remdesivir) — prescribing information, including the outpatient indication and pediatric coverage. fda.gov/drugs
- U.S. Food and Drug Administration. Lagevrio (molnupiravir) — Emergency Use Authorization fact sheet, including the conditions of authorization and the pregnancy statement. fda.gov/…/emergency-use-authorization
- Centers for Disease Control and Prevention. COVID-19 Treatments and Medications — who is considered high risk and the treatment-window guidance. cdc.gov/covid/treatment
- Infectious Diseases Society of America. IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (living guideline) — the therapeutic-management rationale behind first-line versus alternative positioning: nirmatrelvir/ritonavir as the first option for ambulatory patients, remdesivir preferred when drug interactions rule it out, and molnupiravir considered only if neither is available. idsociety.org
Continue Reading
Full Treatment Guide
Outpatient and hospital treatment by severity, including dexamethasone and baricitinib.
COVID Symptoms
What to watch for, and the five-day window that decides antiviral eligibility.
Long COVID
PASC symptoms, risk factors, and the research on whether early antivirals reduce risk.
Debunked Treatments
Hydroxychloroquine, ivermectin and the trials that tested them.
